Beam Therapeutics Inc. Common Stock (BEAM)
Stock · NASDAQ · Health Care
$23.49as of 10/16/2026
Price chart
Active signals
BEAM Signal Track Record
How signals performed across all stocks →What BEAM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 39 | -5.8% | 49% | September 2, 2026 |
| Bollinger Band Breakout | 25 | -0.9% | 40% | August 19, 2026 |
| 200-Day Moving Average TouchActive now | 18 | -4.8% | 44% | August 20, 2026 |
| Bollinger Band BreakdownActive now | 17 | +0.9% | 53% | September 9, 2026 |
| Any 20-session window (baseline) | -1.1% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BEAM
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparti…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 540
- Website
- beamtx.com/
Fundamentals
- 1-day range
- $23.16$24.56
- Market cap
- $2.81B
- P/E (trailing)
- —
- P/E (forward)
- -4.95
- EPS (trailing)
- $-0.81
- Dividend yield
- —
- Beta
- 2.26
- Avg. volume
- 1.83M
How Beam Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 24, 2026 · via SEC EDGAR / Finnhub
Forecasts
13 analyst ratings
Beam Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- BEAMBeam Therapeutics Inc. Common Stock$23.47▼ 5.10%Market cap $2.81BP/E —$20.23$38.26
- TARSTarsus Pharmaceuticals Inc. Common Stock$68.07▼ 4.11%Market cap $2.81BP/E —$53.89$91.53
- KODKodiak Sciences Inc Common Stock$85.75▼ 2.69%Market cap $2.84BP/E —$10.94$104
- IOVAIovance Biotherapeutics Inc. Common Stock$13.62▼ 7.47%Market cap $2.77BP/E —$1.76$15.3
- BCRXBioCryst Pharmaceuticals Inc. Common Stock$7.79▼ 2.87%Market cap $2.36BP/E —$6.23$11.22
- ADMAADMA Biologics Inc Common Stock$10.68▼ 0.47%Market cap $2.34BP/E 13.67$7.21$20.46
- VCELVericel Corporation Common Stock$40.13▼ 2.17%Market cap $2.29BP/E 85.09$28.95$49.32
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BEAM Beam Therapeutics Inc. Common Stock | $2.81B | — | $23.47 | ▼ 5.10% | $20.23$38.26 |
| TARS Tarsus Pharmaceuticals Inc. Common Stock | $2.81B | — | $68.07 | ▼ 4.11% | $53.89$91.53 |
| KOD Kodiak Sciences Inc Common Stock | $2.84B | — | $85.75 | ▼ 2.69% | $10.94$104 |
| IOVA Iovance Biotherapeutics Inc. Common Stock | $2.77B | — | $13.62 | ▼ 7.47% | $1.76$15.3 |
| BCRX BioCryst Pharmaceuticals Inc. Common Stock | $2.36B | — | $7.79 | ▼ 2.87% | $6.23$11.22 |
| ADMA ADMA Biologics Inc Common Stock | $2.34B | 13.67 | $10.68 | ▼ 0.47% | $7.21$20.46 |
| VCEL Vericel Corporation Common Stock | $2.29B | 85.09 | $40.13 | ▼ 2.17% | $28.95$49.32 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Targetbenzinga · 10/15/2026
- Will IP Theft Allegations Against YolTech and Serapha Bio Change Beam Therapeutics' (BEAM) NarrativeYahoo · 10/1/2026
- Beam sues 2 biotechs, alleging theft of base editing trade secretsYahoo · 9/29/2026
- Temporary Weakness in Intellia Stock Seems Like a Buying OpportunityYahoo · 9/29/2026
- Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical ProgressSeekingAlpha · 9/29/2026
- As Claude Enters the Gene-Editing Arena, There’s Still a Long-Term Case for BEAM StockYahoo · 9/28/2026
- Cathie Wood Makes $64 Million Bet on Two StocksYahoo · 9/28/2026
- Prime: A Buy Due To BLA Filing H1 '27 And Continued PM647 AdvancementSeekingAlpha · 9/25/2026
- Squeeze Watch: 10 Stocks With Over 33% Short InterestBenzinga · 9/25/2026
Insider Activity
Insider Actions →- Bethany J. Cavanagh · October 1, 2026 · Sale187 @ $24.41
- Giuseppe Ciaramella · September 24, 2026 · Gift123.4K
- Amy Simon · July 27, 2026 · Sale16.7K @ $25.74
- Amy Simon · June 30, 2026 · Sale373 @ $34.73
- John M. Evans · June 30, 2026 · Option Exercise25.0K @ $1.03
- John M. Evans · June 30, 2026 · Sale1.9K @ $34.84
- John M. Evans · June 30, 2026 · Sale23.1K @ $34.26
- John M. Evans · June 29, 2026 · Option Exercise6.3K @ $1.03
- John M. Evans · June 29, 2026 · Option Exercise18.7K @ $0.67
- John M. Evans · June 29, 2026 · Sale11.6K @ $35.91
- John M. Evans · June 29, 2026 · Sale13.4K @ $35.13
- Giuseppe Ciaramella · June 17, 2026 · Option Exercise29.0K @ $1.03
- Giuseppe Ciaramella · June 17, 2026 · Option Exercise6.5K @ $0.67
- Fishman Mark · June 3, 2026 · Grant19.7K
- Chirfi Guindo · June 3, 2026 · Grant19.7K
Institutional Ownership
March 31, 2026
- Total shares held
- 103.18M
- Total value held
- $2.38B
- Institutional holders
- 245
- Unknown12.45M
- Unknown12.13M
- Unknown10.13M
- Unknown8.49M
- Unknown5.70M
- Unknown4.54M
- Unknown4.38M
- Unknown3.83M
- Unknown3.83M
- Unknown3.68M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Beam Therapeutics to present BEAM-301 data at ESGCT congress
Beam Therapeutics is scheduled to present initial data from its Phase 1/2 trial of BEAM-301 for Glycogen Storage Disease Type Ia at the 33rd Annual Congress of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. This upcoming presentation is a key catalyst for the stock, which is currently trading near the lower end of its 52-week range. The company is also highlighted in a list of high-beta stocks where short sellers are active, suggesting elevated volatility potential around the data release.
Beam Therapeutics to present BEAM-301 data at ESGCT congress. Beam Therapeutics is scheduled to present initial data from its Phase 1/2 trial of BEAM-301 for Glycogen Storage Disease Type Ia at the 33rd Annual Congress of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. This upcoming presentation is a key catalyst for the stock, which is currently trading near the lower end of its 52-week range. The company is also highlighted in a list of high-beta stocks where short sellers are active, suggesting elevated volatility potential around the data release.